Anti-stress and nootropic activity of drugs affecting the renin-angiotensin system in rats based on indirect biochemical evidence
Conclusions:
The present study provides scientific support for the anti-stress and nootropic activities of aliskiren, valsartan and their combination. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 23, 2015 Category: Biomedical Science Authors: Anil Kumar, K., Nagwar, S., Thyloor, R., Satyanarayana, S. Tags: Original Articles Source Type: research
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria
Conclusions:
The addition of aliskiren to optimal conventional therapy provided a higher reduction of blood pressure and urinary albumin excretion when compared with the addition of losartan or ramipril. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 23, 2015 Category: Biomedical Science Authors: Imbalzano, E., Scarpelli, M., Mandraffino, G., Creazzo, M., Lizio, G., Trapani, G., Dattilo, G., Dalbeni, A., Tomasello, C., Sardo, M. A., Saitta, A. Tags: Original Articles Source Type: research
Effects of exercise on central aortic pressure before and after treatment with renin-angiotensin system blockade in patients with hypertension
Conclusion:
Blood pressure lowering does not directly influence the relationship between aortic and brachial pressure either at rest or during exercise in patients with hypertension, other than through proportionate lowering of both pressures. These effects remained unchanged 48 hours after a simulated missed medication dose. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 23, 2015 Category: Biomedical Science Authors: Lacy, P. S., Brunel, P., Baschiera, F., Botha, J., Williams, B. Tags: Original Articles Source Type: research
Nuclear expression of renin-angiotensin system components in NRK-52E renal epithelial cells
Conclusion:
We conclude that the NRK-52E cells express an intracellular RAS localized to the nucleus and may be an appropriate cell model to elucidate the functional relevance of this system. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 23, 2015 Category: Biomedical Science Authors: Alzayadneh, E. M., Chappell, M. C. Tags: Original Articles Source Type: research
Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats
Conclusion:
These results suggest that aliskiren has protective effects against tacrolimus-induced nephrotoxicity; implying that renin inhibitor may counteract nephrotic syndrome associated with immunosuppressant use. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS - December 23, 2015 Category: Biomedical Science Authors: Al-Harbi, N. O., Imam, F., Al-Harbi, M. M., Iqbal, M., Nadeem, A., Al-Shahrah, O. A., Korashy, H. M., Al-Hosaini, K. A., Ahmed, M., Bahashwar, S. Tags: Original Articles Source Type: research
Paricalcitol modulates ace2 shedding and renal adam17 in nod diabetic mice beyond proteinuria.
PARICALCITOL MODULATES ACE2 SHEDDING AND RENAL ADAM17 IN NOD DIABETIC MICE BEYOND PROTEINURIA.
Am J Physiol Renal Physiol. 2015 Dec 23;:ajprenal.00082.2015
Authors: Riera M, Anguiano L, Clotet S, Roca-Ho H, Rebull M, Pascual J, Soler MJ
Abstract
Circulating and renal ACE2 activity is increased in the NOD diabetic mice. Because paricalcitol has been reported to protect against diabetic nephropathy, we investigated the role of paricalcitol in modulating ACE2 in these mice. In addition, renal ADAM17 a metalloprotease implied in ACE2 shedding was assessed. Diabetic NOD females and non...
Source: Am J Physiol Renal P... - December 23, 2015 Category: Urology & Nephrology Authors: Riera M, Anguiano L, Clotet S, Roca-Ho H, Rebull M, Pascual J, Soler MJ Tags: Am J Physiol Renal Physiol Source Type: research
Angiotensinogen Exerts Effects Independent of Angiotensin II.
CONCLUSIONS: AGT contributes to body weight gain and liver steatosis through functions of the des(angiotensin I)AGT domain, which are independent of angiotensin II production.
PMID: 26681751 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - December 17, 2015 Category: Cardiology Authors: Lu H, Wu C, Howatt DA, Balakrishnan A, Moorleghen JJ, Chen X, Zhao M, Graham MJ, Mullick AE, Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW, Daugherty A Tags: Arterioscler Thromb Vasc Biol Source Type: research
Innovative regulatory-conforming bioanalytical approaches enabling systematic investigations of pharmacokinetics and pharmacodynamics by paediatric clinical studies in all age groups
Conclusion
The child-appropriate bioanalytical platform can be applied in upcoming paediatric Phase II and Phase III studies of the LENA (Labeling of Enalapril from Neonates up to Adolescents) project. Meaningful concentration-time profiles with 6–7 sampling points can be obtained even in neonates without infringing ethical recommendations on trial-related blood lost.
The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement n°602295 (LENA). (Source: Archives of Disease in Childhood)
Source: Archives of Disease in Childhood - December 14, 2015 Category: Pediatrics Authors: Burckhardt, B. B., Tins, J., Läer, S. Tags: POSTER PRESENTATIONS Source Type: research
The Vitamin D Receptor Activator Maxacalcitol Provides Cardioprotective Effects in Diabetes Mellitus
Conclusion
Our results suggest that OCT prevents the development of cardiac damage in DM, independent of RAS inhibition. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - November 25, 2015 Category: Cardiology Source Type: research
Effect of aliskiren on vascular remodeling in small retinal circulation
Background: In hypertension changes in small arterial structure are characterized by an increased wall-to-lumen ratio (WLR). These adaptive processes are modulated by the renin angiotensin system. It is unclear whether direct renin inhibitors exert protective effects on small arteries in hypertensive patients. (Source: Artery Research)
Source: Artery Research - November 24, 2015 Category: Cardiology Authors: Christian Ott, Agnes Jumar, Joanna Harazny, Stephanie Schmidt, Roland Schmieder Source Type: research
Two ‐Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non‐Interventional Prospective Study
The authors investigated the long‐term effectiveness and safety of aliskiren (ALIS) with particular attention on its association with dual blockade of the renin‐angiotensin system (RAS). The open, prospective 3A Registry (N=8723) in Germany assigned patients in a 4:1:1 ratio to ALIS, angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), or non‐RAS drugs. Patients taking ALIS compared with those taking ACE inhibitors/ARBs or non‐RAS had more comorbidities and risk factors, were taking more antihypertensive agents, and had higher blood pressure (BP) values at entry. At 2 years, BP...
Source: The Journal of Clinical Hypertension - November 13, 2015 Category: Cardiology Authors: Uwe Zeymer, Ralf Dechend, Thomas Riemer, Evelin Deeg, Jochen Senges, David Pittrow, Roland Schmieder, Tags: Original Paper Source Type: research
Effect of aliskiren on vascular remodelling in small retinal circulation
Conclusion: Thus, our data indicate that treatment with aliskiren, given on top of valsartan therapy, improves altered vascular remodelling in hypertensive patients. (Source: Journal of Hypertension)
Source: Journal of Hypertension - November 12, 2015 Category: Cardiology Tags: ORIGINAL PAPERS: Retina Source Type: research
Abstract 020: A Mitochondrial Renin-Angiotensin System: Internalization of Angiotensinogen [Session Title: Concurrent IX C: Renin Angiotensin System I]
There is compelling evidence for actions of an intracellular renin-angiotensin system (RAS) in various cell organelles including the endoplasmic reticulum, nucleus and the mitochondria (Mito). Indeed, angiotensin (Ang) AT1 and AT2 receptor subtypes were functionally linked to Mito respiration and nitric oxide production, respectively in a previous study. Since elucidation of mitochondrial pathways for expression of RAS protein components as well as Ang II or Ang-(1-7) is equivocal at this time, we undertook a biochemical analysis of the Mito RAS from adult male sheep kidney. Cortical Mito were isolated by differential cent...
Source: Hypertension - November 3, 2015 Category: Cardiology Authors: Wilson, B. A., Pirro, N. T., Gwathmey, T. M., Rose, J. C., Chappell, M. C. Tags: Session Title: Concurrent IX C: Renin Angiotensin System I Source Type: research
Abstract 024: The Direct Renin Inhibitor Aliskiren Improves Vasodilation and Endothelial Function in Resistance Arteries from Diabetic and Hypertensive Patients [Session Title: Concurrent IX C: Renin Angiotensin System I]
In conclusion ALK improved endothelial function and induced vasodilation in resistance arteries from diabetic and hypertensive patients. (Source: Hypertension)
Source: Hypertension - November 3, 2015 Category: Cardiology Authors: Savoia, C., De Ciuceis, C., Arrabito, E., Paini, A., Sada, L., Nicoletti, C., Carletti, R., Rizzoni, D., Muiesan, M. L., Di Giioia, C., Agabiti Rosei, E., Volpe, M. Tags: Session Title: Concurrent IX C: Renin Angiotensin System I Source Type: research
Two‐Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non‐Interventional Prospective Study
The authors investigated the long‐term effectiveness and safety of aliskiren (ALIS) with particular attention on its association with dual blockade of the renin‐angiotensin system (RAS). The open, prospective 3A Registry (N=8723) in Germany assigned patients in a 4:1:1 ratio to ALIS, angiotensin‐converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), or non‐RAS drugs. Patients taking ALIS compared with those taking ACE inhibitors/ARBs or non‐RAS had more comorbidities and risk factors, were taking more antihypertensive agents, and had higher blood pressure (BP) values at entry. At 2 years, BP...
Source: The Journal of Clinical Hypertension - November 1, 2015 Category: Cardiology Authors: Uwe Zeymer, Ralf Dechend, Thomas Riemer, Evelin Deeg, Jochen Senges, David Pittrow, Roland Schmieder, Tags: Original Paper Source Type: research
